Orexo AB (0H19) AI Stock Analysis

Orexo AB

(LSE:0H19)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low current leverageOrexo currently has low debt relative to its equity base, which provides some balance-sheet flexibility despite operating losses. This reduces immediate solvency pressure and may help the company direct available resources toward development programs and business transformation.

Negative Factors

Severe revenue contraction and lossesThe sharp revenue contraction leaves Orexo’s current business base far too small relative to its operating structure, while the very large net loss signals weak earnings absorption. Persistent losses can erode equity and make future growth increasingly dependent on financing or successful launches.

Orexo AB (0H19) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 19.31M
Dividend Yield: ―
Average Volume (3M): 8,153
Price to Earnings (P/E): -0.4
Beta (1Y): -0.39
Revenue Growth: -97.68%
EPS Growth: -83.26%
Country: UK
Employees: 61
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Orexo AB Business Overview & Revenue Model

Company Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatme...

Orexo AB Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:-15.85%|Next Earnings Date:Feb 03, 2027

Earnings Call SentimentPositive

The call had a cautiously positive operational tone, with meaningful progress on Izipry, OX640, OX390, semaglutide, partnerships, and cost restructuring. However, the company continues to face substantial financial pressures, including low revenue, a SEK 118 million loss from continued operations, negative cash flow, reduced own cash of SEK 62 million, large historical Zubsolv-related obligations, and pending regulatory and partnering milestones. The number and importance of development milestones and the planned rights issue outweighed the challenges, supporting an overall positive sentiment.

Positive Updates

Progress in Strategic Transformation

Orexo said it made substantial progress toward becoming a platform-focused company, including restructuring its balance sheet and operations, streamlining costs, and focusing on partnerships around the AmorphOX platform.

Negative Updates

Low Quarterly Revenue

Revenue from continued operations was SEK 0.8 million in Q3. Abstral royalties were low because individual country royalty agreements continue to expire, while Edluar royalties declined following generic product launches in Canada.

Company Guidance

Orexo expects Izipry to have a six months of review time, with approval expected in the end of Q1 next year; OX640 is on track to start its pivotal trial in Q4, with results expected in first half of next year, potentially into the beginning of Q2, and the company expects to announce the trial start also in this quarter. Normalized OpEx was SEK 55 million or SEK 18 million per month, but the 18 is higher than where they are aiming, and OpEx is expected to further decline in 2027, with cash flow getting closer to the EBITDA; the ambition is to have a runway taking the company past 2027 without income from partnering. The Zubsolv earn-out is expected in Q1 of next year, BARDA resource contribution is up to $54 million, and the DOJ payment is provisioned at up to $4 million over several years, while no significant numbers are foreseen from Zubsolv rebates moving from now on.

Orexo AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0H19 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	80Outperform	SEK 40.76B	59.09	15.54%	―	<0.01%	-6.75%
SE:SOBI	72Outperform	SEK 169.16B	25.62	15.99%	―	14.79%	26766.85%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ALZCUR	48Neutral	SEK 882.54M	42.87	65.99%	―	―	―
SE:IRLAB.A	42Neutral	SEK 310.81M	-3.21	-97.06%	―	4.74%	66.33%
SE:XSPRAY	41Neutral	SEK 559.52M	-3.06	-26.00%	―	―	44.46%

* Healthcare Sector Average

Performance Comparison

GB:0H19 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0H19	Orexo AB	5.15	-22.90	-81.64%
SE:SOBI	Swedish Orphan Biovitrum Ab	490.20	166.60	51.48%
SE:CAMX	Camurus AB	673.00	46.00	7.34%
SE:ALZCUR	AlzeCure Pharma AB	6.40	4.51	238.45%
SE:IRLAB.A	IRLAB Therapeutics AB Class A	2.09	-0.40	-15.90%
SE:XSPRAY	Xspray Pharma AB	11.80	-12.80	-52.04%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Orexo AB AI Stock Analysis